How can clinical research improve European health outcomes in cancer?

Selby, Peter J.; Liu, Lifang; Downing, Amy; Banks, Ian; Wilson, Roger; Stephens, Richard; Meunier, Françoise; Rochon, Justine; Morris, Eva; Seymour, Michel; Gregory, Walter M.; Lawler, Mark; Boaz, Annette

doi:10.1016/j.jcpo.2019.100182

Cited by 11 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumour registries are important to assist with planning and allocation of health care resources for the management and outcomes of NB in LMICs 30,31 . Presenting the data in open platforms, which have been limited thus far, provides the collaborative partnerships that have advanced other oncology priorities 32–34 .…”

Section: Discussionmentioning

confidence: 99%

“…Tumour registries are important to assist with planning and allocation of health care resources for the management and outcomes of NB in LMICs. 30,31 Presenting the data in open platforms, which have been limited thus far, provides the collaborative partnerships that have advanced other oncology priorities. [32][33][34] By documenting operational data, an improved understanding into the indications of treatment, and as important, the reasons why treatments were not indicated may be examined.…”

Section: Ta B L Ementioning

confidence: 99%

See 1 more Smart Citation

Neuroblastoma: The basis for cure in limited‐resource settings

Heerden

Kruger

Esterhuizen

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Neuroblastoma (NB) contributes the most to the mortality of childhood malignancies worldwide. The disease spectrum is heterogenous and the management complex and costly, especially in advanced disease or disease with adverse biology. In low-and middle-income countries (LMICs) the majority of NB presents in advanced stages. Therefore, with limited resources and poor prognosis the treatment of NB is often not a priority. The aim of the study was to evaluate the research activities and perceptions of the management of NB that determine the research and treatment approaches in LMICs. Methods: Data were sourced from https://www.clinicaltrials.gov/ identifying NB trials open to LMIC. Abstracts on NB research presented at the International Society for Paediatric Oncology (SIOP) Congresses between 2014 and 2020 were evaluated according to income status. An online survey evaluating medical views on NB in LMICs and the effect on the management was conducted. Descriptive analysis was done. Where appropriate categorical association between covariates was assessed using the Pearson chi-square (χ 2 ) test or Fishers exact test. Results: There were 15/562 (2.7%) trials open to LMIC. Only six of 138 (4.3%) LMIC participated in NB trials. Of the 688 abstracts presented between 2014 and 2020 at the SIOP International Congress on NB as primary subject, 297 (42.7%) were from LMICs. Only two were from low-income countries (LICs). Sixty-one countries responded to the NB survey. Positive views towards NB management were present when treatment was based on a national protocol, the availability of trimodal or advanced treatment options were present, and when a balance of metastatic or local disease were treated. Conclusion: Management of NB in LMICs should include increased advocacy and research as well as implementation of national management strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Ta B L Ementioning

confidence: 99%

Neuroblastoma: The basis for cure in limited‐resource settings

Heerden

Kruger

Esterhuizen

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…There is substantial evidence that the patients who are treated in researchactive hospitals have better outcomes than those who are not. 11 7. You have a right to discuss with your healthcare team your priorities and preferences to achieve the best possible quality of life.…”

Section: The European Code Of Cancer Practicementioning

confidence: 99%

Implementing the European Code of Cancer Practice to Improve Europe’s Cancer Outcomes

Lawler¹,

Oliver²,

Gijssels³

et al. 2021

Oncology &Amp; Haematology

Self Cite

View full text Add to dashboard Cite

“…Research is an essential aspect of high quality CRC care systems 10 . Patients treated at research‐active hospitals have better outcomes than those who are not 11 . However, to date there has been little systematic consideration of the state of global CRC research.…”

Section: Introductionmentioning

confidence: 99%

Global colorectal cancer research, 2007‐2021: Outputs and funding

Begum

Lewison

Wang

et al. 2022

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to provide an evidence base for colorectal cancer research activity that might influence policy, mainly at the national level. Improvements in healthcare delivery have lengthened life expectancy, but within a situation of increased cancer incidence. The disease burden of CRC has risen significantly, particularly in Africa, Asia and Latin America. Research is key to its control and reduction, but few studies have delineated the volume and funding of global research on CRC. We identified research papers in the Web of Science (WoS) from 2007 to 2021, and determined the contributions of the leading countries, the research domains studied, and their sources of funding. We identified 62 716 papers, representing 5.7% of all cancer papers. This percentage was somewhat disproportionate to the disease burden (7.7% in 2015), especially in Eastern Europe. International collaboration increased over the time period in almost all countries except in China. Genetics, surgery and prognosis were the leading research domains. However, research on palliative care and quality‐of‐life in CRC was lacking. In Western Europe, the main funding source was the charity sector, particularly in the UK, but in most other countries government played the leading role, especially in China and the USA. There was little support from industry. Several Asian countries provided minimal contestable funding, which may have reduced the impact of their CRC research. Certain countries must perform more CRC research overall, especially in domains such as screening, palliative care and quality‐of‐life. The private‐non‐profit sector should be an alternative source of support.

show abstract

How can clinical research improve European health outcomes in cancer?

Cited by 11 publications

References 39 publications

Neuroblastoma: The basis for cure in limited‐resource settings

Neuroblastoma: The basis for cure in limited‐resource settings

Implementing the European Code of Cancer Practice to Improve Europe’s Cancer Outcomes

Global colorectal cancer research, 2007‐2021: Outputs and funding

Contact Info

Product

Resources

About